Not enough history yet — the model records CNS's score after each daily run, and the chart appears once a few days have accumulated.
CNS at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
| 30-day change | -2.9% |
|---|---|
| 90-day change | -0.2% |
| Forward EPS estimate | $3.87 |
Over the last 90 days, what analysts expect CNS to earn is essentially unchanged. The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
Cohen & Steers, Inc. (CNS): score, valuation & FAQ
Cohen & Steers, Inc. (CNS) is an Asset Management company. As a bank, insurer or REIT it runs on a different financial model from the rest of the market, so Bull Rankings grades it on a sector-appropriate card — price-to-book, dividend yield, payout ratio and cash-flow coverage — rather than the 0–100 quality-growth score used elsewhere. The read below is a transparent screen, not a buy recommendation.
Its strongest graded signals are ROE (A-) and Yield (B+), while P/B (D) rate weaker.
Is CNS a good stock to buy?
Bull Rankings grades CNS on a sector-appropriate card — price-to-book, dividend yield, payout and cash-flow coverage — rather than a single quality-growth score. That is driven by ROE (A-) and Yield (B+). A score is a quantitative screen of Cohen & Steers, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
How does Bull Rankings grade CNS?
As a bank, insurer or REIT, CNS isn't given a quality-growth score — signals like free cash flow, debt-to-equity and P/E don't translate cleanly to a balance-sheet business. Instead it's graded on a sector-appropriate card: price-to-book, dividend yield, payout ratio and operating-cash-flow coverage, where it rates strongest on ROE (A-) and Yield (B+) and weakest on P/B (D).
Is CNS overvalued or undervalued?
We don't publish a discounted-cash-flow value for CNS, and not because the business is unprofitable. For a lender, insurer or property trust, "free cash flow" measures balance-sheet growth rather than owner earnings — loan originations and repayments run through operating cash flow — so discounting it would produce a confident-looking number with nothing behind it. CNS is judged on book value, return on equity and income cover instead, which is what the financial-strength card shows.
What are the main risks of investing in CNS?
Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
New to these metrics? See the guides and the methodology.